Company intelligence / Profile preview

Neko Health

Ownership: Private
Development stage: Commercial

Overview

Neko Health has completed over 10,000 commercial scans since its February 2023 launch. Clinical results show that about 14.1% of scanned individuals required medical intervention and approximately 1% received potentially life-saving diagnoses for serious cardiovascular or oncological conditions—none of whom were previously aware of their illness. The company’s approach enables early detection and prevention through rapid, non-invasive scanning with immediate doctor consultation.

Therapeutic areas: Metabolic DisordersCardiovascularDermatology
Modalities: Device (medical devices for diagnostics)Non-pharmacological therapy (preventative screening)AI-powered diagnostics
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on Neko Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neko Health.

Explore the full profile